


T-1-PMPA

Cat. No.:	HY-158149
CAS No.:	1323883-62-0
Molecular Formula:	C ₁₆ H ₁₇ N ₅ O ₃
Molecular Weight:	327.34
Target:	EGFR; Apoptosis
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	T-1-PMPA is a potent EGFR inhibitor with apoptotic properties. T-1-PMPA effectively inhibits EGFR ^{WT} and EGFR ^{T790M} , with IC ₅₀ values of 86 nM and 561.73 nM, respectively ^[1] .									
IC₅₀ & Target	EGFR ^{WT} 86 nM (IC ₅₀)	EGFR ^{T790M} 561.73 nM (IC ₅₀)								
In Vitro	<p>T-1-PMPA (0.312-10 μM; 24 h) shows significant suppression of the proliferation of HepG2 and MCF7 malignant cell lines, with IC₅₀ values of 3.51 μM and 4.13 μM, respectively^[1]. In HepG2 cells, T-1-PMPA increases the proportion of cells in the early stage of apoptosis from 0.77 to 29.17%, the late stage of apoptosis from 0.17 to 8.81%, and the overall stage from 3.05 to 42.03%. Additionally, the percentage of necrotic cells increased to 4.05% compared to 2.21% in the control cells. The qRT-PCR analysis further supported the apoptotic effects by revealing significant increases in the levels of caspase-3 and caspase-9. T-1-PMPA controls the levels of TNFα and IL2 by 74 and 50%^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 and MCF7 malignant cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0.312 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed significant suppression of the proliferation of HepG2 and MCF7 malignant cell lines.</td> </tr> </table>		Cell Line:	HepG2 and MCF7 malignant cell lines	Concentration:	0.312 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM	Incubation Time:	24 h	Result:	Showed significant suppression of the proliferation of HepG2 and MCF7 malignant cell lines.
Cell Line:	HepG2 and MCF7 malignant cell lines									
Concentration:	0.312 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM									
Incubation Time:	24 h									
Result:	Showed significant suppression of the proliferation of HepG2 and MCF7 malignant cell lines.									

REFERENCES

[1]. Ibrahim H Eissa, et al. New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and In Vitro Studies. ACS Omega. 2024 Mar 27;9(14):15861-15881.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA